Tax addback for pharma marketing expenses

Summary#

HF 5147, titled “Income and corporate franchise tax provisions modified, and addition for pharmaceutical marketing expenses required,” would amend Minnesota’s individual income and corporate franchise tax laws. It would require certain pharmaceutical marketing expenses deducted under federal tax law to be added back when calculating Minnesota tax. The bill’s stated goal is to require that addback; the bill is at first reading and is not law.

  • For both individual income tax and corporate franchise tax, a filer would have to add back the amount deducted under federal law for qualifying direct-to-consumer pharmaceutical marketing.
  • The bill defines that marketing to include advertising and promotion aimed at US consumers, plus certain patient outreach and disease-awareness campaigns funded by a pharmaceutical manufacturer and linked to a specific product.
  • The change would apply to taxable years beginning after December 31, 2026.

What it means for you#

  • Tax filers: If you file a Minnesota individual income or corporate franchise tax return and deducted qualifying marketing expenses under federal law, you would have to add that amount back for Minnesota tax purposes.
  • Pharmaceutical manufacturers: The bill defines pharmaceutical manufacturers and uses that definition in describing qualifying campaigns. It does not ban or otherwise restrict pharmaceutical marketing.
  • Other taxpayers: The bill does not directly change tax rates or federal tax deductions.

Money#

No cost or revenue estimate is available in the supplied material.

  • The addback would increase the Minnesota income used to calculate tax for affected filers. The resulting tax or state revenue change is not estimated.
  • No spending, fee, fine, or staffing requirement is stated.

What is unclear#

  • The underlying current tax statutes were not supplied, so I could not verify whether similar addbacks already apply or how much of this would be new.
  • The bill does not explain how to divide costs when a campaign is only partly directed at consumers or linked to a specific product.
  • It does not set out recordkeeping rules, guidance, or a process for resolving disputes over which expenses qualify.
  • It does not estimate how many filers would be affected or the size of their tax changes.

Case for#

  • A possible argument for the bill is that Minnesota would no longer allow these expenses to reduce the income used to calculate state tax, even when they are deducted under federal law.
  • The bill identifies the kinds of consumer marketing it covers, including some product-linked outreach and disease-awareness campaigns, rather than applying the addback to all business advertising.
  • Applying the rule to both individual income and corporate franchise tax calculations could cover qualifying deductions reported through different kinds of tax returns.

Case against#

  • One concern is that the definition includes a wide range of promotion, including patient outreach and disease-awareness campaigns, and the bill gives no detailed rules for deciding which costs qualify.
  • Affected filers could owe more Minnesota tax, but the bill provides no estimate of the amounts or who would bear the largest changes.
  • The bill does not explain how tax officials or filers should handle mixed-purpose campaigns or disagreements about whether a campaign is linked to a specific product.